OMO-1
MET-driven cancers (e.g., NSCLC)
Phase 1Active (Partnered)
Key Facts
Indication
MET-driven cancers (e.g., NSCLC)
Phase
Phase 1
Status
Active (Partnered)
Company
About Octimet Oncology
Octimet Oncology is a private, clinical-stage biotech developing targeted kinase inhibitors for oncology, with a primary focus on the MET pathway. Its lead asset, OMO-1, is a highly selective oral MET inhibitor that has completed Phase 1 studies, while OMO-2 is a pre-clinical dual MET/RAS pathway inhibitor. The company has de-risked its development path through regional partnerships with Shanghai Allist for Greater China and DeuterOncology for the Rest of the World, positioning it to advance its pipeline with external funding and expertise. Octimet operates as a virtual or lean organization, leveraging partnerships to progress its innovative biomarker-based clinical strategies.
View full company profile